

ESMO Virtual Advanced Course on CAR-T and Next Generation Cell Therapies in Haematology and Solid Tumours

Programme

**ESMO VIRTUAL
ADVANCED COURSE**

25-26 JUNE 2021

Co-Chairs

Chiara Bonini, Italy

Fiona Thistlethwaite, United Kingdom

ESMO VIRTUAL ADVANCED COURSE PROGRAMME

CAR-T AND NEXT GENERATION CELL THERAPIES

IN HAEMATOLOGY AND SOLID TUMOURS

25-26 June 2021

CO-CHAIRS:	Chiara Bonini, Italy Fiona Thistlethwaite, United Kingdom	SPEAKERS:	Christian Chabannon, France Paolo Corradini, Italy Hermann Einsele, Germany Alvaro Urbano Ispizua, Spain Ulrike Köhl, Germany Jürgen Kuball, Netherlands Sara Mastaglio, Italy Paolo Morgese, Belgium Sophie Papa, United Kingdom
-------------------	--	------------------	---

LEARNING OBJECTIVES

- To learn the biological basis and mechanism of action of CAR-T and other engineered T cell therapy products
- To learn the major clinical results and toxicities observed in CAR-T cell therapy trials and in the real-life use of CAR-T cells
- To understand the major challenges related to the clinical use of CAR-T cells
- To learn and discuss the most innovative T cell therapy approaches

ACCREDITATION

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered CEST (Central European Summer Time)

Friday, 25 June 2021

09:00-09:10 10'	Welcome and course overview Fiona Thistlethwaite, UK and Chiara Bonini, IT
09:10-10:10 25'	Session 1 - Where are we now? Haematology (CD19 CAR-T) Paolo Corradini, IT
25'	Solid tumours (melanoma TIL, CAR-T, TCR gene modified cells NYESO + new developments) Fiona Thistlethwaite, UK
10'	Discussion
10:10-10:30	Break
10:30-11:55 25'	Session 2 - New approaches New targets (BCMA, CD20 plus dual targeting) Hermann Einsele, DE
25'	Genetic manipulation (Genome editing, gene modified TIL, armoured CARS) Chiara Bonini, IT
25'	New cell types (NK, universal CAR-T) Ulrike Köhl, DE
10'	Discussion
11:55-12:50 25'	Session 3 - Optimising access to cell therapies: Regulatory and funding issues – part 1 Developing institutional readiness (Facilities, ambulatory care, cell storage/processing, education and training) Christian Chabannon, FR
20'	Health registries Jürgen Kuball, NL
10'	Discussion

Saturday, 26 June 2021

09:00-09:30	Session 3 - Optimising access to cell therapies: Regulatory and funding issues – part 2
20'	Health economic models Paolo Morgese, BE
10'	Discussion
9:30-11:55	Workshop sessions 15' Introduction based on clinical cases presented by speakers 30' Discussion
09:30-10:15 45'	Workshop 1 Toxicity management (CRS, ICANS) Sara Mastaglio, IT
10:15-10:25	Break
10:25-11:10 45'	Workshop 2 Manufacturing challenges: manufacturing models, centralised manufacture vs decentralised vs local manufacture, commercial vs academic manufacture, standardisation of processes (apheresis, cryopreservation, thawing) Alvaro Urbano Ispizua, ES
11:10-11:55 45'	Workshop 3 Modifying the tumour microenvironment – e.g. including use of checkpoint inhibitors, preconditioning regime, use of IL2 (still used in melanoma TIL) Sophie Papa, UK
11:55-12:10	Feedback on the workshops from each group
12:10-12:20	Conclusion and farewell